Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the best CBD stocks to buy right now. The stock has gained almost 40% year-to-date, and analysts see more upside in it.
According to Jazz Pharmaceuticals’ Q1 2026 results released on May 5, revenue from CBD-based epilepsy drug Epidiolex rose 15% YoY to $250 million in that quarter. The increase was driven by continued strong demand for Epidiolex, which is used to treat severe forms of epilepsy. Outside the US, Epidiolex is marketed under the Epidyolex brand name.
Jazz has partnered with Nippon Zoki to commercialize Epidyolex in Japan as it works to expand the drug’s market. Epidiolex was Jazz’s second-largest business by revenue contribution in Q1 after the company’s sleep franchise.
Jazz’s consolidated revenue from the various business lines came to $1.1 billion, reflecting an increase of 19% YoY. The company delivered a net income of $293.1 million, compared with a net loss of $92.5 million a year ago.
Looking ahead, Jazz Pharmaceuticals anticipates full-year 2026 revenue of between $4.25 billion and $4.5 billion. The company is advancing its pipeline projects as it seeks to fuel long-term growth.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is a biopharmaceutical company whose programs include cannabinoid therapeutics. Its CBD-based blockbuster drug Epidiolex is used to treat severe epilepsy. The company was founded in 2003 and is based in Ireland.
While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Most Buzzing AI Semiconductor Stocks to Buy in 2026 and 11 Best Medical Technology Stocks to Buy Right Now.
Disclosure: None. Follow Insider Monkey on Google News.